| Livmarli (maralixibat) / Mirum Pharma |
NCT03353454: A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) |
|
|
| Withdrawn | 3 | 0 | NA | Maralixibat, SHP625, Placebo | Mirum Pharmaceuticals, Inc. | Progressive Familial Intrahepatic Cholestasis (PFIC) | 06/20 | 06/20 | | |
| Completed | 3 | 93 | Europe, Canada, US, RoW | Maralixibat, Formerly LUM001 and SHP625, Placebo | Mirum Pharmaceuticals, Inc. | Progressive Familial Intrahepatic Cholestasis (PFIC) | 09/22 | 09/22 | | |
NCT05543187: A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) |
|
|
| Active, not recruiting | 3 | 5 | Japan | TAK-625, Maralixibat chloride | Takeda | Progressive Familial Intrahepatic Cholestasis (PFIC) | 09/23 | 07/25 | | |
NCT05543174: A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS) |
|
|
| Active, not recruiting | 3 | 7 | Japan | TAK-625, Maralixibat chloride | Takeda | Alagille Syndrome (ALGS) | 10/23 | 07/25 | | |
| Active, not recruiting | 3 | 90 | Europe, Canada, US, RoW | Maralixibat | Mirum Pharmaceuticals, Inc. | Progressive Familial Intrahepatic Cholestasis (PFIC) | 12/24 | 12/24 | | |
NCT06553768: Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) |
|
|
| Recruiting | 3 | 90 | Europe, US, RoW | Maralixibat, Formerly LUM001, SHP625, Placebo | Mirum Pharmaceuticals, Inc. | Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | 09/26 | 02/27 | | |
NCT06413368: Maralixibat in Patients With Cystic Fibrosis and Constipation, A Within-Subjects Pilot Study |
|
|
| Not yet recruiting | 2/3 | 20 | US | Maralixibat 9.5 MG/ML [Livmarli] | Children's Hospital Los Angeles | Constipation Chronic Idiopathic, Cystic Fibrosis | 06/26 | 06/27 | | |
